Kiniksa posts FY 2025 ARCALYST net product revenue of USD 677.6 million (62% YoY)

Kiniksa reported Q4 FY2025 total revenue of USD 202.1 million, up 65.0%, driven by ARCALYST net product revenue of USD 202.1 million. Total operating expenses were USD 182.4 million, including USD 70.0 million in collaboration expenses and USD 10.2 million in non-cash share-based compensation. Q4 net income was USD 14.2 million. For FY2025, Kiniksa posted total revenue of USD 677.6 million and net income of USD 59.0 million. FY operating expenses were USD 600.3 million, including USD 229.5 million in collaboration expenses and USD 37.0 million in non-cash share-based compensation. ARCALYST FY net product revenue was USD 677.6 million, with 62% year-over-year sales growth; FY gross-to-net was 8.4%. Cash, cash equivalents and short-term investments were USD 414.1 million at December 31, 2025, with no debt. Operationally, Kiniksa said ARCALYST adoption continued in recurrent pericarditis, with about 18% of an estimated 14,000 multiple-recurrence patients actively on therapy at the end of Q4, more than 4,150 prescribers since launch, and average total duration of therapy approaching 3 years. The company expects 2026 ARCALYST net product revenue of USD 900 million to USD 920 million and said its current operating plan is expected to remain cash flow positive annually. In the pipeline, Kiniksa expects Phase 2/3 dose-focusing data for KPL-387 in recurrent pericarditis in H2 2026 and plans to initiate a Phase 1 first-in-human trial for KPL-1161 by the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240730PRIMZONEFULLFEED1001166337) on February 24, 2026, and is solely responsible for the information contained therein.